Stephane M. Oudard

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 320 publications

Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.

Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 26, 2026

Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET.

Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 19, 2026

Correction: Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.

Correction: Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.

Journal: British journal of cancer

Published: January 20, 2026

Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12.

Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 07, 2026

Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.

Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.

Journal: NPJ precision oncology

Published: November 21, 2025

Real-World Outcomes of First-Line Immune-Based Combination Therapies in Bone-Metastatic Clear Cell Renal Cell Carcinoma.

Real-World Outcomes of First-Line Immune-Based Combination Therapies in Bone-Metastatic Clear Cell Renal Cell Carcinoma.

Journal: Clinical genitourinary cancer

Published: October 09, 2025

Feasibility of standard versus fractionated carboplatin-paclitaxel in older adults with ovarian cancer: a retrospective study.

Feasibility of standard versus fractionated carboplatin-paclitaxel in older adults with ovarian cancer: a retrospective study.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: August 06, 2025

PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: Rationale, Mechanisms, and Clinical Applications.

PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: Rationale, Mechanisms, and Clinical Applications.

Journal: European urology oncology

Published: July 15, 2025

GABA promotes resistance to immunotherapy in patients with TLS-positive tumors.

GABA promotes resistance to immunotherapy in patients with TLS-positive tumors.

Journal: Cancer cell

Published: July 10, 2025

Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study.

Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study.

Journal: British journal of cancer

Published: June 25, 2025

Fake It till You Predict It: Data Augmentation Strategies to Detect Initiation and Termination of Oncology Treatment.

Fake It till You Predict It: Data Augmentation Strategies to Detect Initiation and Termination of Oncology Treatment.

Journal: Studies in health technology and informatics

Published: May 17, 2025

Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study.

Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study.

Journal: European urology

Published: March 24, 2025

Showing 1-12 of 320

Last Updated: 09/26/2026